Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size and Its Estimated Growth Rate?
The market size for glucagon-like peptide (GLP)-1 agonists weight loss medications has seen impressive growth in recent times. Projected to expand from $13.38 billion in 2024 to $15.63 billion in 2025, the market will experience a compound annual growth rate (CAGR) of 16.9%. The expansion during the historic period can be ascribed to factors such as increasing obesity incidence, rising cases of type 2 diabetes, enhanced knowledge about health risks related to obesity, elevated healare spending, greater attention to managing chronic illnesses, and better access to healare services.

Anticipated to experience a swift rise in its expansion, the market size for glucagon-like peptide (GLP) -1 agonists weight loss drugs is projected to reach a value of $28.91 billion in 2029, escalating at a compound annual growth rate (CAGR) of 16.6%. Several factors contribute to this growth anticipated in the forecast period, including the escalating demand for potent weight loss methods, extension of drug indications beyond diabetes, heightened investments in research and development, adopting more personalized medications, and an increase in awareness due to direct-to-consumer marketing strategies. Key trends that are expected during the forecast timeframe include the creation of oral glucagon-like peptide (GLP)-1 formulations, advances in sustained-release medication delivery, the inclusion of digital health technologies for monitoring, implementation of artificial intelligence in discovering and developing drugs, and innovations in peptide engineering to enhance efficacy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp

How Are Emerging Segments Shaping the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Landscape?
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market covered in this report is segmented -

1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs
2) By Route of Administration: Parenteral, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

Subsegments:
1) By Semaglutide: Ozempic, Wegovy, Rybelsus
2) By Liraglutide: Saxenda, Victoza
3) By Tirzepatide: Mounjaro, Zepbound
4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp

Which Growth Factors Are Influencing Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Expansion?
An increase in obesity rates is anticipated to fuel the upward trajectory of the GLP-1 agonist weight loss drug market. This medical condition, known as obesity, is typified by an unhealthy accumulation of body fat that poses a risk to wellbeing. Unhealthy diets, typified by excessive consumption of fast food and sugary beverages, lacking nutritional balance, leads to increasing obesity rates. As the number of people affected by obesity-related health complications increase, the demand for effective treatments escalates, boosting the use of GLP-1 agonist weight loss drugs because of their demonstrated ability to promote weight loss and improve metabolic health. For example, the World Health Organization, a Switzerland-based intergovernmental organization, reported in March 2024 that, in 2022, every eighth person worldwide was obese. Out of the 2.5 billion adults who were overweight, roughly 890 million were classified as obese. Moreover, it was found that about 43% of the global adult population was overweight, with 16% categorized as obese. Hence, the escalating rates of obesity are driving growth in the GLP-1 agonist weight loss drug market.

Who Are the Dominant Players Across Different Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segments?
Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.

What Trends Are Driving Growth in The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Key players in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are advancing groundbreaking obesity treatments to raise efficacy and boost patient results. These treatments involve therapies that simulate the GLP-1 hormone to control hunger, increase the feeling of fullness, and facilitate weight loss. These medications aid in managing obesity by enhancing metabolic activity and endorsing sustainable weight control. For example, in November 2023, US pharmaceutical firm, Eli Lilly and Company, received approval from the US Food and Drug Administration for Zepbound, a chronic weight management drug for adults suffering from obesity or overweight along with associated ailments like type 2 diabetes or sleep apnea. The drug functions by triggering GIP and GLP-1 hormone receptors to curb hunger and amplify metabolic activity.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-glp-1-agonists-weight-loss-drugs-global-market-report

Which Geographic Regions Are Expected to Dominate the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market in the Coming Years?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
2. What is the CAGR expected in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
3. What Are the Key Innovations Transforming the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry?
4. Which Region Is Leading the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.